| Cardiology and Cardiovascular Medicine | Lifetime | 276 | PL 3 | 99.64 |
| Family Practice | Lifetime | 11 | PL 1 | 99.13 |
| Nutrition and Dietetics | Lifetime | 305 | PL 2 | 98.61 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 578 | PL 3 | 98.17 |
| Nephrology | Lifetime | 234 | PL 2 | 98.11 |
| Geriatrics and Gerontology | Lifetime | 400 | PL 2 | 88.25 |
| Family Practice | 2021-2025 | 5 | PL 2 | 97.11 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 216 | PL 5 | 98.46 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 348 | PL 4 | 91.38 |
| Nephrology | 2021-2025 | 232 | PL 2 | 85.58 |
| Nutrition and Dietetics | 2021-2025 | 501 | PL 11 | 64.57 |
| Medication Adherence and Compliance | Lifetime | 10 | PL 1 | 99.54 |
| Blood Pressure and Hypertension Studies | Lifetime | 95 | PL 1 | 99.61 |
| Hormonal Regulation and Hypertension | Lifetime | 98 | PL 1 | 99.39 |
| Renal function and acid-base balance | Lifetime | 65 | PL 1 | 98.78 |
| Electrolyte and hormonal disorders | Lifetime | 79 | PL 1 | 98.87 |
| Sodium Intake and Health | Lifetime | 43 | PL 1 | 99.03 |
| Renin-Angiotensin System Studies | Lifetime | 80 | PL 1 | 98.88 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 152 | PL 1 | 98.34 |
| Pharmaceutical Economics and Policy | Lifetime | 165 | PL 2 | 97.43 |
| Renal and Vascular Pathologies | Lifetime | 334 | PL 2 | 97.88 |
| Chronic Kidney Disease and Diabetes | Lifetime | 503 | PL 2 | 97.36 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 227 | PL 1 | 95.40 |
| Cardiovascular Health and Disease Prevention | Lifetime | 913 | PL 8 | 96.31 |
| Potassium and Related Disorders | Lifetime | 189 | PL 2 | 96.45 |
| Dialysis and Renal Disease Management | Lifetime | 897 | PL 9 | 96.36 |
| Pharmacology and Obesity Treatment | Lifetime | 499 | PL 1 | 94.92 |
| Ion Transport and Channel Regulation | Lifetime | 852 | PL 1 | 93.84 |
| Erythropoietin and Anemia Treatment | Lifetime | 846 | PL 16 | 89.68 |
| Medication Adherence and Compliance | 2021-2025 | 3 | PL 1 | 98.44 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 70 | PL 1 | 98.48 |
| Hormonal Regulation and Hypertension | 2021-2025 | 62 | PL 1 | 97.09 |
| Pharmaceutical studies and practices | 2021-2025 | 83 | PL 2 | 93.85 |
| Bipolar Disorder and Treatment | 2021-2025 | 532 | PL 13 | 86.66 |
| Renal and Vascular Pathologies | 2021-2025 | 481 | PL 3 | 83.16 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 752 | PL 5 | 85.77 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 808 | PL 7 | 84.92 |
| Sodium Intake and Health | 2021-2025 | 256 | PL 4 | 81.73 |
| Potassium and Related Disorders | 2021-2025 | 494 | PL 8 | 67.90 |
| Electrolyte and hormonal disorders | 2021-2025 | 662 | PL 16 | 66.63 |
| Renal function and acid-base balance | 2021-2025 | 667 | PL 14 | 57.08 |
